Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: The Wilmot Cancer Institute experience

Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: The Wilmot Cancer Institute experience

The purpose of this study was to explore the associations between age and frailty with immune-related adverse events (irAEs) among patients with cutaneous malignancies receiving immune checkpoint inhibitor (ICI) therapy. A retrospective review of all patients receiving ipilimumab, nivolumab, or pemb...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of geriatric oncology 2020-04, Vol.11 (3), p.496-502
Hauptverfasser: Archibald, William J., Victor, Adrienne I., Strawderman, Myla S., Maggiore, Ronald J.
Format: Artikel
Sprache:eng
Schlagworte:
Geriatric assessment
Immune related adverse events
Immunotherapy
Ipilimumab
Melanoma
Merkel cell carcinoma
Nivolumab
Older adult
Pembrolizumab
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The purpose of this study was to explore the associations between age and frailty with immune-related adverse events (irAEs) among patients with cutaneous malignancies receiving immune checkpoint inhibitor (ICI) therapy. A retrospective review of all patients receiving ipilimumab, nivolumab, or pembrolizumab for treatment of cutaneous malignancies at the Wilmot Cancer Institute between 1 Jan 2011 and 3 Apr 2017. A total of 120 patients (age
ISSN:1879-4068
1879-4076
DOI:10.1016/j.jgo.2019.07.005